Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 8/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.38 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | EPOR | P19235 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | GLP1R | P43220 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31697430 | 0.92 | EPHX2 (0.44) | EPHX2MEN1MAPTKMT2ASLC6A5 | |
| SCHEMBL15773390 | 0.85 | EPHX2 (0.47) | EPHX2PRMT1KDM4ELMNATSHR | |
| SCHEMBL22271542 | 0.85 | EPHX2 (0.47) | EPHX2PRMT1KDM4ELMNATSHR | |
| SCHEMBL29975232 | 0.82 | TSHR (0.43) | EPHX2MEN1MAPTKMT2ASLC6A5 | |
| SCHEMBL18878659 | 0.82 | PRMT1 (0.53) | EPHX2MEN1MAPTKMT2ASLC6A5 | |
| SCHEMBL20353234 | 0.80 | EPHX2 (0.43) | EPHX2PRMT1KDM4EGLP1R | |
| SCHEMBL20353219 | 0.80 | EPHX2 (0.43) | EPHX2PRMT1KDM4EGLP1R | |
| SCHEMBL20353132 | 0.80 | EPHX2 (0.43) | EPHX2PRMT1KDM4EGLP1R | |
| SCHEMBL20353221 | 0.80 | EPHX2 (0.43) | EPHX2PRMT1KDM4EGLP1R | |
| SCHEMBL24982646 | 0.80 | EPHX2 (0.43) | EPHX2PRMT1KDM4EGLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4100404-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| WO-2021158707-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. (US) | 2021-08-12 | — | — | WO | disclosed |